Protalix BioTherapeutics, Inc.
Hedge Funds Holdings
Last updated:
Protalix BioTherapeutics, Inc.‘s stocks are currently a part of 20 hedge funds’ portfolios, which represents 4.13% of the total amount of its stocks outstanding. This makes up a total of 2.00M shares of Protalix BioTherapeutics, Inc.. Compared to the previous quarter, the number fell by -43.79% or -1.55M shares fewer. As for the holding position changes, 20% (4) of current hedge fund investors increased the number of shares held, 20% (4) of current holders sold a part of the shares held, and 15% (3) closed the holdings completely. 8 hedge funds are new holders of Protalix BioTherapeutics, Inc. stock in Q1 2023, it is 40% of total holders.
Hedge funds holding Protalix BioTherapeutics (Q2 2018 – Q1 2023)
| Q2 2018 | 31 |
|---|---|
| Q3 2018 | 35 |
| Q4 2018 | 29 |
| Q1 2019 | 26 |
| Q2 2019 | 25 |
| Q3 2019 | 25 |
| Q4 2019 | 8 |
| Q1 2020 | 13 |
| Q2 2020 | 25 |
| Q3 2020 | 22 |
| Q4 2020 | 21 |
| Q1 2021 | 35 |
| Q2 2021 | 32 |
| Q3 2021 | 34 |
| Q4 2021 | 23 |
| Q1 2022 | 27 |
| Q2 2022 | 25 |
| Q3 2022 | 24 |
| Q4 2022 | 24 |
| Q1 2023 | 20 |
Hedge funds changes in Protalix BioTherapeutics positions (Q2 2018 – Q1 2023)
| Q2 2018 | 3 | 7 | 7 | 5 | 9 |
|---|---|---|---|---|---|
| Q3 2018 | 9 | 9 | 5 | 5 | 7 |
| Q4 2018 | 1 | 8 | 6 | 7 | 7 |
| Q1 2019 | 2 | 6 | 5 | 5 | 8 |
| Q2 2019 | 6 | 4 | 2 | 7 | 6 |
| Q3 2019 | 3 | 3 | 8 | 3 | 8 |
| Q4 2019 | 8 | 0 | 0 | 25 | -25 |
| Q1 2020 | 5 | 3 | 2 | 0 | 3 |
| Q2 2020 | 16 | 4 | 1 | 4 | 0 |
| Q3 2020 | 2 | 8 | 4 | 5 | 3 |
| Q4 2020 | 8 | 1 | 5 | 9 | -2 |
| Q1 2021 | 18 | 10 | 3 | 4 | 0 |
| Q2 2021 | 11 | 10 | 5 | 14 | -8 |
| Q3 2021 | 7 | 10 | 10 | 5 | 2 |
| Q4 2021 | 3 | 7 | 9 | 13 | -9 |
| Q1 2022 | 9 | 4 | 8 | 5 | 1 |
| Q2 2022 | 4 | 6 | 5 | 5 | 5 |
| Q3 2022 | 3 | 3 | 7 | 5 | 6 |
| Q4 2022 | 4 | 8 | 4 | 3 | 5 |
| Q1 2023 | 8 | 4 | 4 | 3 | 1 |
Hedge funds changes in Protalix BioTherapeutics stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 17,000 | 34,000 |
|---|---|---|
| Q3 2018 | 23,000 | 233,000 |
| Q4 2018 | 22,000 | 81,000 |
| Q1 2019 | 6,000 | 188,000 |
| Q2 2019 | 46,000 | 142,000 |
| Q3 2019 | 20,000 | 50,000 |
| Q4 2019 | 9,000 | 1,000 |
| Q1 2020 | 123,000 | 6,000 |
| Q2 2020 | 1,148,000 | 12,000 |
| Q3 2020 | 658,000 | 93,000 |
| Q4 2020 | 378,000 | 343,000 |
| Q1 2021 | 1,084,000 | 1,233,000 |
| Q2 2021 | 2,864,000 | 2,532,000 |
| Q3 2021 | 1,571,000 | 1,417,000 |
| Q4 2021 | 140,000 | 614,000 |
| Q1 2022 | 735,000 | 218,000 |
| Q2 2022 | 1,631,000 | 218,000 |
| Q3 2022 | 988,000 | 110,000 |
| Q4 2022 | 1,412,162 | 124,574 |
| Q1 2023 | 1,267,075,000 | 1,260,000 |